Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734474 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,202
- Enrollment target
NCT00734474: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00734474 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,202 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (804% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00734474, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,202 participants
- Enrollment target
Study Summary
This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metformin.
Primary Outcome
Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.
Interventions
- DRUG Metformin
- DRUG Sitagliptin
- DRUG Placebo tablet
- DRUG LY2189265
- DRUG Placebo solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,202 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
What the finished NCT00734474 record still lists
NCT00734474 is an interventional study that assigns participants to a tested intervention. Its 1,202 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (804% higher).
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT00734474 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00734474 about?
NCT00734474 is a clinical study titled "A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin". This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metfo...
What is the current status of trial NCT00734474?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,202 participants. The study started on 2008-08. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00734474?
The interventions under investigation include: Metformin (DRUG), Sitagliptin (DRUG), Placebo tablet (DRUG), LY2189265 (DRUG), Placebo solution (DRUG).
Who is sponsoring clinical trial NCT00734474?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00734474's enrollment target sits among peer trials
1,202 17th of 2000 higher than 1,984 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07038785 · 1,204 participants
Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia